Physicians and health care groups have lined up to support the Value in Health Care Act, which could create new incentives to adopt value-based care.
Health care organizations are lining up to support federal legislation that could create new incentives for physicians and health care organizations to adopt value-based care.
Federal lawmakers introduced the Value in Health Care Act of 2023 and a number of physician and medical groups quickly announced their endorsements.
The legislation “would make commonsense changes to Medicare’s Alternative Payment Models (APMs) program to incentivize greater participation in value-based health programs.” It would help increase participation in accountable care organizations (ACOs) that are designed to improve quality of care and health outcomes for seniors, while lower costs, said an announcement from Representative Suzan DelBene (D, Oregon), a cosponsor of the bill. Additional sponsors are Representatives Darin LaHood (R, Illinois), Kim Schrier, MD, (D, Washington), Brad Wenstrup, DPM (R, Ohio), Earl Blumenauer (D, Oregon), and Larry Bucshon, MD (R, Indiana).
Representative Suzan DelBene (D, Oregon) is a cosponsor of the Value in Health Care Act, which could create new incentives to adopt value-based care.
“Physicians and hospitals participating in Alternative Payment Models are leading the changes our health care system needs to focus on value instead of volume,” DelBene said in the announcement. "Providers should be paid based on the quality of the care they deliver, not the quantity of services. The Value in Health Care Act would encourage more providers to join these models and accelerate this change, leading to improved quality of care and health outcomes for seniors."
The lawmakers’ announcement said the Value in Health Care Act would make the following changes to the APM and ACO parameters:
If approved, the legislation would extend the 5% advanced APM incentive payment as practices transition from fee-for-service care to value-based care, according to the Medical Group Management Association (MGMA).
“In light of another round of proposed cuts to Medicare physician reimbursement, ensuring group practices have the necessary support to succeed in value-based care arrangements is paramount,” MGMA Senior Vice President of Government Affairs Anders Gilberg said in a statement. “MGMA looks forward to working with Congress to ensure the passage of this crucial piece of legislation.”
The bill also would freeze the 50% revenue threshold that physicians in value-based care models must meet to qualify for the incentive payments, according to the American Medical Association (AMA).
The legislation would give the HHS secretary the authority to further increase the revenue threshold but at a more gradual pace—no more than 5% in a given year, AMA President Jesse M. Ehrenfeld, MD, MPH, said in a statement.
“These proposed policies would grant HHS the needed flexibility to adjust the financial risk at a pace that enables more physicians to participate in APMs, while building on the tremendous movement toward value-based care," Ehrenfeld said.
MGMA and AMA both were part of a joint letter of support published July 27 by the American Hospital Association. The additional supporters on that letter were Accountable for Health, American Academy of Family Physicians, American Academy of Orthopaedic Surgeons, the American College of Physicians, America’s Essential Hospitals, America’s Physician Groups, AMGA, the Association of American Medical Colleges, Federation of American Hospitals, Healthcare Leadership Council, Health Care Transformation Task Force, the National Association of ACOs, and National Rural Health Association Premier Inc.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More